Celaid Therapeutics Inc. (Head office: Bunkyo-ku, Tokyo; President: Nobuyuki Arakawa) has announced a third-party allotment of new shares with The University of Tokyo Edge Capital Partners Co., Ltd. as the lead investor, Tsukuba Institute of Research, Ltd. and SBI Regional Revitalization Support Corporation, and Techno Science Co. The total amount of funds raised is approximately 500 million yen.
With this financing, Celaid will further accelerate the development of cell therapy products for blood cancers such as acute leukemia.
Celaid Therapeutics' Business
Blood cancers such as leukemia are on the increase due to an aging population, and further development of curative therapies is awaited not only in Japan but also in many other countries around the world. The regenerative medicine products under research and development at Celaid Therapeutics will expand the possibilities of transplantation as a curative treatment for various blood cancers, and are expected to be utilized in the treatment of many patients as next-generation cell therapy products.
＜ Purpose of fundraising ＞
Celaid Therapeutics plans to use the funds raised to conduct large-scale studies using immunodeficient mice in Japan and to work toward obtaining preclinical POC data. Celaid is already negotiating with various partners to establish a supply chain in the U.S. These include manufacturers of its initial therapeutic product to be manufactured in compliance with the FDA's regulatory requirements.
Nobuyuki Arakawa, President and CEO, Celaid Therapeutics Inc.
"We are very pleased to secure the necessary funds for future product development in our Series A round, a key milestone in our financing pathway, by meeting with investors who recognize the potential of our technology and the significance of our contribution to society. With the expectations of each investor in mind, we will further promote our product development activities."